{"entity":{"id":"vorinostat","kind":"drug","name":"Vorinostat","aka":["SAHA","Suberoylanilide hydroxamic acid"],"tldr":"Vorinostat (Zolinza) was the first drug of its kind, a capsule that loosens the chemical packaging of DNA. It treats the skin disease of cutaneous T-cell lymphoma after two other treatments have failed.","summary":"Vorinostat was approved by the FDA in October 2006 for cutaneous manifestations of cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease on or after two systemic therapies, on two open-label studies (response rate about 30% in the pivotal single-arm study of 74 patients). It was the first histone deacetylase inhibitor approved for any cancer and remains a standard option in refractory mycosis fungoides and Sezary syndrome; a European application was withdrawn and it is not authorised in the EU. Fatigue, diarrhoea, thrombocytopenia, taste change and QT prolongation are the main adverse effects; thromboembolism is a class warning.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Vorinostat","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vorinostat"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/vorinostat"}],"tags":["nci-list"],"related":["romidepsin","bexarotene"],"cancers":[],"sections":[],"technologies":["epigenetic-drugs"],"targets":["hdac"],"drugs":[],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Cutaneous T-cell lymphoma has no cancer record yet."],"brand":"Zolinza","modality":"Small-molecule pan-HDAC inhibitor (hydroxamate)","mechanism":"Inhibits class I (HDAC1, 2, 3) and class II (HDAC6) histone deacetylases at nanomolar concentrations, causing histone hyperacetylation, re-expression of silenced genes, cell-cycle arrest and apoptosis.","approvals":[{"region":"US","year":2006,"indication":"Cutaneous manifestations of CTCL with progressive, persistent or recurrent disease after two systemic therapies"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vorinostat/","neighbours":{"drug":[{"id":"bexarotene","kind":"drug","name":"Bexarotene","route":"/drugs/bexarotene/"},{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"}],"target":[{"id":"hdac","kind":"target","name":"Histone deacetylases (HDAC)","route":"/targets/hdac/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"mycosis-fungoides","kind":"cancer","name":"Mycosis fungoides","route":"/cancers/mycosis-fungoides/"},{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/"}],"paper":[{"id":"paper-mavoric-mogamulizumab-lancet-oncol-2018","kind":"paper","name":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","route":"/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}],"trial":[{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/"}]}}